TC BioPharm (Holdings) PLC (TCBP)
0.82
-0.01
(-1.20%)
USD |
NASDAQ |
Jun 28, 16:00
0.83
+0.01
(+1.22%)
After-Hours: 20:00
TC BioPharm Research and Development Expense (Annual): 9.670M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 9.670M |
| December 31, 2022 | 9.402M |
| December 31, 2021 | 8.470M |
| Date | Value |
|---|---|
| December 31, 2020 | 8.573M |
| December 31, 2019 | 11.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
8.470M
Minimum
2021
11.00M
Maximum
2019
9.423M
Average
9.402M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| Adaptimmune Therapeutics PLC | 126.51M |
| NuCana PLC | 31.19M |
| Autolus Therapeutics PLC | 130.48M |
| Cellectis SA | 87.65M |